Welcome to our dedicated page for Casi Pharmaceuticals SEC filings (Ticker: CASIF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Casi Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Casi Pharmaceuticals's regulatory disclosures and financial reporting.
CASI Pharmaceuticals’ major shareholder updates its ownership and financing details. Wei-Wu He, Ph.D. and affiliated entities report beneficial ownership of 23,985,535 Ordinary Shares, representing 58.8% of the class, based on 20,555,873 shares outstanding as of May 15, 2026.
The filing reflects multiple holdings, including options and several convertible notes. On April 17, 2026, ETP Global III Fund L.P. purchased a new US$5 million convertible note, the fourth tranche of a US$20 million financing. This note can convert into Ordinary Shares between US$1 and US$2 per share, with the beneficial ownership calculation assuming a US$1 conversion price and including shares acquirable within 60 days.
CASI Pharmaceuticals’ major shareholder updates its ownership and financing details. Wei-Wu He, Ph.D. and affiliated entities report beneficial ownership of 23,985,535 Ordinary Shares, representing 58.8% of the class, based on 20,555,873 shares outstanding as of May 15, 2026.
The filing reflects multiple holdings, including options and several convertible notes. On April 17, 2026, ETP Global III Fund L.P. purchased a new US$5 million convertible note, the fourth tranche of a US$20 million financing. This note can convert into Ordinary Shares between US$1 and US$2 per share, with the beneficial ownership calculation assuming a US$1 conversion price and including shares acquirable within 60 days.
CASI Pharmaceuticals, Inc. reports 2025 results showing continued revenue pressure and deep losses while warning of substantial doubt about its ability to continue as a going concern. Revenue fell to US$20.7 million from US$28.5 million in 2024 as sales of key oncology drug EVOMELA® declined amid intensified generic competition, and FOLOTYN® sales in China ceased after license renewal was not granted.
The company recorded a 2025 net loss of US$48.1 million and used US$20.8 million of cash in operating activities. Cash and cash equivalents dropped to US$5.6 million at year-end, with net current liabilities of US$36.2 million and an accumulated deficit of US$748.1 million. Management states that additional liquidity will be required over the next 12 months and outlines plans such as equity financing, expense reductions, new credit facilities and potential asset or license sales.
CASI continues to invest in its pipeline, spending US$6.3 million on research and development in 2025, including programs like CID‑103 and BI‑1206, and increasing its stake in Precision Autoimmune Therapeutics Co., Ltd. through equity purchases. It also raised capital via ordinary share issuances and a US$20 million convertible note program with a fund controlled by Executive Chairman Dr. Wei‑Wu He. The company notes a default under certain financial covenants tied to a long-term borrowing, giving a convertible note holder the right to demand immediate repayment, and classifies that note as a current liability, further underscoring its tight liquidity position.
CASI Pharmaceuticals, Inc. reports 2025 results showing continued revenue pressure and deep losses while warning of substantial doubt about its ability to continue as a going concern. Revenue fell to US$20.7 million from US$28.5 million in 2024 as sales of key oncology drug EVOMELA® declined amid intensified generic competition, and FOLOTYN® sales in China ceased after license renewal was not granted.
The company recorded a 2025 net loss of US$48.1 million and used US$20.8 million of cash in operating activities. Cash and cash equivalents dropped to US$5.6 million at year-end, with net current liabilities of US$36.2 million and an accumulated deficit of US$748.1 million. Management states that additional liquidity will be required over the next 12 months and outlines plans such as equity financing, expense reductions, new credit facilities and potential asset or license sales.
CASI continues to invest in its pipeline, spending US$6.3 million on research and development in 2025, including programs like CID‑103 and BI‑1206, and increasing its stake in Precision Autoimmune Therapeutics Co., Ltd. through equity purchases. It also raised capital via ordinary share issuances and a US$20 million convertible note program with a fund controlled by Executive Chairman Dr. Wei‑Wu He. The company notes a default under certain financial covenants tied to a long-term borrowing, giving a convertible note holder the right to demand immediate repayment, and classifies that note as a current liability, further underscoring its tight liquidity position.
CASI Pharmaceuticals, Inc. director Thomas Folinsbee filed a Form 3 detailing his initial beneficial ownership in stock options on the company’s ordinary shares. The options are fully vested and exercisable as of the filing date.
Disclosed positions include options over 11,231 ordinary shares at an exercise price of $1.26 per share expiring on July 21, 2035, and options over 20,000 shares at $3.59 per share expiring on June 26, 2034. Additional fully vested options cover 11,231 shares at $2.67 per share expiring on June 18, 2034, and 11,231 shares at $1.93 per share expiring on April 14, 2033.
CASI Pharmaceuticals, Inc. director Thomas Folinsbee filed a Form 3 detailing his initial beneficial ownership in stock options on the company’s ordinary shares. The options are fully vested and exercisable as of the filing date.
Disclosed positions include options over 11,231 ordinary shares at an exercise price of $1.26 per share expiring on July 21, 2035, and options over 20,000 shares at $3.59 per share expiring on June 26, 2034. Additional fully vested options cover 11,231 shares at $2.67 per share expiring on June 18, 2034, and 11,231 shares at $1.93 per share expiring on April 14, 2033.
CASI Pharmaceuticals director Zeng Xuebo has filed a Form 3 disclosing existing stock option holdings. The filing lists three fully vested and exercisable options, each linked to 11,231 ordinary shares.
The options carry exercise prices of $1.26, $2.67, and $1.93 per share and expire on July 21, 2035, June 18, 2034, and April 14, 2033, respectively. No new share purchases or sales are reported; the form simply records current derivative positions.
CASI Pharmaceuticals director Zeng Xuebo has filed a Form 3 disclosing existing stock option holdings. The filing lists three fully vested and exercisable options, each linked to 11,231 ordinary shares.
The options carry exercise prices of $1.26, $2.67, and $1.93 per share and expire on July 21, 2035, June 18, 2034, and April 14, 2033, respectively. No new share purchases or sales are reported; the form simply records current derivative positions.
CASI Pharmaceuticals, Inc. filed a Form 6-K announcing that it has terminated the role of its Global Chief Medical Officer, Dr. Alexander A. Zukiwski, without cause, effective April 20, 2026. The change is described as part of efforts to further streamline the company’s U.S. branches, personnel and related activities.
The company is seeking a new Global Chief Medical Officer to support its long-term business plan. In the interim, certain responsibilities previously handled by Dr. Zukiwski are being taken over by other team members, primarily by Dr. Junping Chen, the company’s China Chief Medical Officer.
CASI Pharmaceuticals, Inc. filed a Form 6-K announcing that it has terminated the role of its Global Chief Medical Officer, Dr. Alexander A. Zukiwski, without cause, effective April 20, 2026. The change is described as part of efforts to further streamline the company’s U.S. branches, personnel and related activities.
The company is seeking a new Global Chief Medical Officer to support its long-term business plan. In the interim, certain responsibilities previously handled by Dr. Zukiwski are being taken over by other team members, primarily by Dr. Junping Chen, the company’s China Chief Medical Officer.
CASI Pharmaceuticals, Inc. completed the fourth and final tranche of its US$20 million convertible note financing with ETP Global III Fund LP, a partnership controlled by Chairman Dr. Wei-Wu He. The latest note has a US$5 million principal amount, matures in 36 months, and bears 12% annual interest.
Both CASI and the purchaser can elect to convert the note into ordinary shares at a price based on the volume weighted average closing price over five trading days, subject to a US$1–US$2 per share conversion price range.
CASI Pharmaceuticals, Inc. completed the fourth and final tranche of its US$20 million convertible note financing with ETP Global III Fund LP, a partnership controlled by Chairman Dr. Wei-Wu He. The latest note has a US$5 million principal amount, matures in 36 months, and bears 12% annual interest.
Both CASI and the purchaser can elect to convert the note into ordinary shares at a price based on the volume weighted average closing price over five trading days, subject to a US$1–US$2 per share conversion price range.
CASI Pharmaceuticals, Inc. General Counsel Wei R Gao filed a Form 3 reporting existing holdings of stock options on the company’s ordinary shares. The filing lists multiple options to buy shares at exercise prices of $1.93, $2.67, and $5.78 per share with expirations between 2031 and 2034. Footnotes state that these options are fully vested and exercisable as of the filing date, and some are performance-based options that become exercisable upon achieving a specified performance target.
CASI Pharmaceuticals, Inc. General Counsel Wei R Gao filed a Form 3 reporting existing holdings of stock options on the company’s ordinary shares. The filing lists multiple options to buy shares at exercise prices of $1.93, $2.67, and $5.78 per share with expirations between 2031 and 2034. Footnotes state that these options are fully vested and exercisable as of the filing date, and some are performance-based options that become exercisable upon achieving a specified performance target.
CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases, reported that its ordinary shares began trading on the OTCQB market under the ticker CASIF on April 14, 2026.
The information in this report is incorporated by reference into the company’s existing shelf registration statements on Form F-3, allowing it to be used in connection with those offerings. The report also reiterates standard forward-looking statement cautions under the U.S. Private Securities Litigation Reform Act of 1995.
CASI Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases, reported that its ordinary shares began trading on the OTCQB market under the ticker CASIF on April 14, 2026.
The information in this report is incorporated by reference into the company’s existing shelf registration statements on Form F-3, allowing it to be used in connection with those offerings. The report also reiterates standard forward-looking statement cautions under the U.S. Private Securities Litigation Reform Act of 1995.
CASI Pharmaceuticals, Inc. filed an initial ownership report showing that Global Controller Qian Kun holds several stock option awards on the company’s ordinary shares. The options cover different blocks of shares with exercise prices of $1.93, $2.67, and $5.78 per share and expire between 2032 and 2034. Footnotes state that the options are fully vested and exercisable as of the reporting date, and that some are performance based and become exercisable upon achievement of a performance target.
CASI Pharmaceuticals, Inc. filed an initial ownership report showing that Global Controller Qian Kun holds several stock option awards on the company’s ordinary shares. The options cover different blocks of shares with exercise prices of $1.93, $2.67, and $5.78 per share and expire between 2032 and 2034. Footnotes state that the options are fully vested and exercisable as of the reporting date, and that some are performance based and become exercisable upon achievement of a performance target.
CASI Pharmaceuticals, Inc. executive Huang Hai, the Global Chief Commercial Officer, reported existing holdings of stock options on Ordinary Shares. The filing lists several option awards with exercise prices of $6.61 and $2.67 per share, expiring in 2034. Some options are fully vested and exercisable as of the form date, while certain performance-based options become exercisable only upon achievement of specified performance targets.
CASI Pharmaceuticals, Inc. executive Huang Hai, the Global Chief Commercial Officer, reported existing holdings of stock options on Ordinary Shares. The filing lists several option awards with exercise prices of $6.61 and $2.67 per share, expiring in 2034. Some options are fully vested and exercisable as of the form date, while certain performance-based options become exercisable only upon achievement of specified performance targets.